Detail akcie Eli Lilly online

Business Summary: Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Eli Lilly And Co revenues increased 56% to $19.8B. Net income increased from $2.76B to $7.4B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Acquired in-Process Research and Deve decrease of 63% to $584M (expense). Dividend per share increased from $1.50 to $1.73.